NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Analysis

Tonix Pharmaceuticals Holding Corp. (TNXP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TNXP

$5.43

−$0.35 (−6.06%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TNXP with… →

TNXP Key Statistics

As of Oct 21, 2026
Trading
Open
$5.85
Previous Close
$5.78
Day's Range
5.40–6.03
52-Week Range
5.40–20.58
Volume
873.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.79
Valuation
Market Cap
$93.13M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.20
EPS (ttm)Profit attributable to each share over the last twelve months.
−13.06
Financials (FY)
Revenue (FY)
$13.11M+29.85%
Net Income (FY)
−$124.02M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
17.15M
1-Year Return
−72.44%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
623.03K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TNXP closed at $5.43, −72.44% over 1 year.

Tonix Pharmaceuticals Holding Corp. (TNXP) has a market capitalization of $93.13M.

In fiscal 2025, TNXP reported revenue of $13.11M.

TNXP Stock Return by Calendar Year

Tonix Pharmaceuticals Holding Corp. (TNXP) return since Dec 2024: what $10,000 became

1 year
$10,000 $2,756
−72.44%
Since Dec 2024
$10,000 $953
−90.47%

If you had invested $10,000 in Tonix Pharmaceuticals Holding Corp. (TNXP) at the close on December 19, 2024, the earliest close on record here, it would have been worth $953 at the close on October 21, 2026: −90.47% in total, −72.19% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−65.24%
2025−52.67%
2024 (partial year)−42.11%

As of October 21, 2026.

TNXP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$13.11M−$124.02M−946.2%
2024$10.09M−$130.04M−1,288.3%
2023$7.77M−$116.66M−1,501.8%
2022$0.00−$110.22M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$13.11M$6.47M−$122.69M−$124.02M−946.2%
2024$10.09M$2.33M−$75.15M−$130.04M−1,288.3%
2023$7.77M$3.03M−$118.38M−$116.66M−1,501.8%
2022$0.00$0.00−$112.09M−$110.22M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TNXP Valuation vs Biotechnology Median

Median of 608 stocks
MetricTNXPBiotechnology medianvs median
P/S ratio3.2013.300.2x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Tonix Pharmaceuticals Holding Corp. (TNXP) at $93.13M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 142.

The most recent close on file for TNXP is $5.43, dated October 21, 2026. That is −$0.35 (−6.06%) against the previous close. Over the past 52 weeks the price has ranged from $5.40 to $20.58. The latest close sits 0.65% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $13.11M. Against the prior fiscal year total of $10.09M, that is a change of +29.85%. The same year closed with a net loss of $124.02M. Earnings per share on a trailing basis come to −13.06.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $13.11M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 3.2 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 1.79. Daily returns over the trailing 1 year annualize to a volatility of 71.05%. Over the trailing twelve months the total return is −72.44%. The stored price history starts on December 19, 2024, and the total return since then is −90.47%.

Growth & Income

No dividend is on file for TNXP.

So far in 2026 the total return is −65.24%. The record holds one complete calendar year, 2025, which returned −52.67%.

Peer Comparison

Tonix Pharmaceuticals Holding Corp. (TNXP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tonix Pharmaceuticals Holding Corp. TNXP $93.13M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Tonix Pharmaceuticals Holding Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Visit website →